NCT06087536 - A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2026

Conditions

Hospital-acquired Bacterial PneumoniaVentilator-associated Bacterial Pneumonia

Interventions

DRUG

OMN6

"Cohort 1: 50 mg x 3/day Cohort 2: 100 mg x 3/day Cohort 3: 150 mg x 3/day~3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days"

DRUG

Placebo

3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days

Trial Locations (4)

Unknown

RECRUITING

Omnix Medical Research Site, Be’er Ya‘aqov

RECRUITING

Omnix Medical Research Site, Holon

RECRUITING

Omnix Medical Research Site, Petah Tikva

RECRUITING

Omnix Medical Research Site, Rishon LeZiyyon